Abstract:
A method for extracting rare earth elements from aqueous solution, comprising: (i) acidifying an aqueous solution containing said rare earth elements with an inorganic acid to result in an acidified aqueous solution containing said rare earth elements and containing the inorganic acid in a concentration of 1-12 M, wherein said rare earth elements are selected from lanthanides, actinides, or combination thereof; and (ii) contacting the acidified aqueous solution with an aqueous-insoluble hydrophobic solution comprising a rare earth extractant compound dissolved in an aqueous-insoluble hydrophobic solvent to result in extraction of one or more of the rare earth elements into the aqueous-insoluble hydrophobic solution by binding of the rare earth extractant compound to the one or more rare earth elements, wherein the rare earth extractant compound has the structure of Formula (1) provided that at least one of the conditions (a)-(d) applies.
Abstract:
The present invention provides commercial processes for preparing 2- ((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-l-((S)-l-(isopropylsulfonyl)-3-methylbutan-2-yl)-3 -m ethyl-2-oxopiperi din-3 -yl)acetic acid as well as intermediates thereof.
Abstract:
Therapeutic methods and pharmaceutical compositions for treating cancer including a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis in a human subject are described. In certain embodiments, the invention includes therapeutic methods of treating a MPN using a MDM2 inhibitor of Formula (I) or Formula (II).
Abstract:
The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPRl) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.
Abstract:
The object of the invention is a process for the preparation of 1-(4-methoxyphenyl)-7-oxo-6-[4- (2-oxopiperidin- 1-yl)phenyl]-4,5,6,7-tetrahydro-1 H -pyrazolo[3,4-c]pyridine-3-carboxylic acid amide of formula 1 (apixaban), as well as the intermediates used in the process.
Abstract:
The invention relates to compounds and composition for the treatment and prevention of cancer. The invention also covers all diseases that may be treated by selective modulation of levels of reactive oxygen species in diseased cells versus normal cells. Methods for the preparation and administration of such compositions are also disclosed.
Abstract:
Bibliotecas de N-(1-Fenil-2-oxo-3-piperidil)sulfonamidas para la identificación de actividad biológica y farmacológica. Continuamente se están buscando nuevos compuestos para el tratamiento y prevención de trastornos. La invención está relacionada con bibliotecas de N-(1-Fenil-2-oxo-3-piperidil)sulfonamidas que son útiles para ser rastreadas biológica y farmacológicamente, para contribuir en la búsqueda e identificación de nuevos compuestos cabeza de serie capaces de modular la actividad funcional de una diana biológica.
Abstract:
The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.